» Articles » PMID: 37496661

A Reactive Oxygen Species-related Signature to Predict Prognosis and Aid Immunotherapy in Clear Cell Renal Cell Carcinoma

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Jul 27
PMID 37496661
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Clear cell renal cell carcinoma (ccRCC) is a malignant disease containing tumor-infiltrating lymphocytes. Reactive oxygen species (ROS) are present in the tumor microenvironment and are strongly associated with cancer development. Nevertheless, the role of ROS-related genes in ccRCC remains unclear.

Methods: We describe the expression patterns of ROS-related genes in ccRCC from The Cancer Genome Atlas and their alterations in genetics and transcription. An ROS-related gene signature was constructed and verified in three datasets and immunohistochemical staining (IHC) analysis. The immune characteristics of the two risk groups divided by the signature were clarified. The sensitivity to immunotherapy and targeted therapy was investigated.

Results: Our signature was constructed on the basis of glutamate-cysteine ligase modifier subunit (GCLM), interaction protein for cytohesin exchange factors 1 (ICEF1), methionine sulfoxide reductase A (MsrA), and strawberry notch homolog 2 (SBNO2) genes. More importantly, protein expression levels of GCLM, MsrA, and SBNO2 were detected by IHC in our own ccRCC samples. The high-risk group of patients with ccRCC suffered lower overall survival rates. As an independent predictor of prognosis, our signature exhibited a strong association with clinicopathological features. An accurate nomogram for improving the clinical applicability of our signature was constructed. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses showed that the signature was closely related to immune response, immune activation, and immune pathways. The comprehensive results revealed that the high-risk group was associated with high infiltration of regulatory T cells and CD8+ T cells and more benefited from targeted therapy. In addition, immunotherapy had better therapeutic effects in the high-risk group.

Conclusion: Our signature paved the way for assessing prognosis and developing more effective strategies of immunotherapy and targeted therapy in ccRCC.

Citing Articles

Prognostic role of dynamic changes in inflammatory indicators in patients with non-small cell lung cancer treated with immune checkpoint inhibitors-a retrospective cohort study.

Guo L, Li J, Wang J, Chen X, Cai C, Zhou F Transl Lung Cancer Res. 2024; 13(8):1975-1987.

PMID: 39263031 PMC: 11384502. DOI: 10.21037/tlcr-24-637.


Mathematical and Machine Learning Models of Renal Cell Carcinoma: A Review.

Sofia D, Zhou Q, Shahriyari L Bioengineering (Basel). 2023; 10(11).

PMID: 38002445 PMC: 10669004. DOI: 10.3390/bioengineering10111320.

References
1.
Lin E, Liu X, Liu Y, Zhang Z, Xie L, Tian K . Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. Front Immunol. 2021; 12:653358. PMC: 7970116. DOI: 10.3389/fimmu.2021.653358. View

2.
Chen X, Song M, Zhang B, Zhang Y . Reactive Oxygen Species Regulate T Cell Immune Response in the Tumor Microenvironment. Oxid Med Cell Longev. 2016; 2016:1580967. PMC: 4980531. DOI: 10.1155/2016/1580967. View

3.
Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

4.
Kitamura T, Qian B, Pollard J . Immune cell promotion of metastasis. Nat Rev Immunol. 2015; 15(2):73-86. PMC: 4470277. DOI: 10.1038/nri3789. View

5.
Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernandez-Pello S . European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019; 75(5):799-810. DOI: 10.1016/j.eururo.2019.02.011. View